

Global Women's Healthcare Market Size study, by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Premarin, Actonel) by Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G8960FFFC5CAEN.html>

Date: January 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G8960FFFC5CAEN

Abstracts

The Global Women's Healthcare Market, valued at approximately USD 29.23 billion in 2023, is forecasted to expand at an impressive compound annual growth rate (CAGR) of 13.20% from 2024 to 2032, reaching an estimated USD 89.22 billion by the end of the forecast period. Women's healthcare represents a dynamic and multifaceted domain, pivotal in addressing a myriad of health challenges unique to the female demographic. From managing fertility and reproductive health to addressing chronic conditions such as osteoporosis and menopause-related complications, the market's trajectory underscores its indispensable role in the global healthcare landscape.

The burgeoning demand for effective healthcare solutions is fueled by advancements in pharmacological interventions, with innovative drugs like Prolia and Mirena redefining standards in therapeutic care. Groundbreaking products continue to shape the market, addressing complex conditions such as postmenopausal osteoporosis and endometriosis. The increasing prevalence of these conditions, combined with rising awareness about women's health, has amplified the adoption of both preventive and therapeutic measures. Additionally, the market is experiencing a surge in research and development investments, targeting new drug formulations and delivery systems aimed at enhancing patient compliance and outcomes.

Despite the market's robust growth, it grapples with significant challenges. High drug

costs and limited access to specialized treatments in underdeveloped regions hinder widespread adoption. Furthermore, stringent regulatory frameworks and protracted drug approval processes create barriers for new entrants. However, ongoing public and private partnerships, particularly in advancing accessibility and affordability, present promising avenues for stakeholders. These collaborative efforts are further complemented by a heightened focus on patient-centric care, leveraging technology to personalize treatment regimens.

Regionally, North America leads the women's healthcare market, driven by advanced healthcare infrastructure, significant healthcare spending, and a proactive approach to women's health awareness. Europe closely follows, benefiting from favorable government policies and substantial investments in research activities. Meanwhile, the Asia-Pacific region is poised for the fastest growth, underpinned by improving healthcare facilities, a burgeoning middle class, and an increasing focus on addressing women-centric health issues in countries such as India and China.

Major market players included in this report are:

Bayer AG

Amgen Inc.

Pfizer Inc.

Merck & Co., Inc.

Teva Pharmaceutical Industries Ltd.

AbbVie Inc.

Eli Lilly and Company

Ferring Pharmaceuticals

Novo Nordisk A/S

Johnson & Johnson

Lupin Limited

Allergan plc

Sun Pharmaceutical Industries Ltd.

Sanofi S.A.

Novartis International AG

The detailed segments and sub-segment of the market are explained below:

By Drugs:

Prolia

Xgeva

Evista

Mirena

Zometa

Reclast

Nuvaring

Premarin

Actonel

By Application:

Female Infertility

Postmenopausal Osteoporosis

Endometriosis

Contraception

PCOS (Polycystic Ovary Syndrome)

Menopause

By Region:

North America:

U.S.

Canada

Europe:

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific:

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America:

Brazil

Mexico

Middle East & Africa:

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional-level analysis for each market segment.

Detailed analysis of the geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approaches.

Analysis of competitive structure of the market.

Demand-side and supply-side analysis of the market

Contents

CHAPTER 1. GLOBAL WOMEN'S HEALTHCARE MARKET EXECUTIVE SUMMARY

1.1. GLOBAL WOMEN'S HEALTHCARE MARKET SIZE & FORECAST (2022-2032)

- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drugs
 - 1.3.2. By Application
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL WOMEN'S HEALTHCARE MARKET DEFINITION AND RESEARCH ASSUMPTIONS

2.1. RESEARCH OBJECTIVE

- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL WOMEN'S HEALTHCARE MARKET DYNAMICS

3.1. MARKET DRIVERS

- 3.1.1. Rising Awareness and Demand for Women's Health Products

- 3.1.2. Advancements in Pharmaceutical Research and Development
- 3.1.3. Increasing Prevalence of Chronic Diseases Among Women
- 3.2. Market Challenges
 - 3.2.1. High Cost of Specialized Treatments
 - 3.2.2. Limited Access in Underdeveloped Regions
- 3.3. Market Opportunities
 - 3.3.1. Innovations in Drug Formulations
 - 3.3.2. Strategic Partnerships and Collaborations
 - 3.3.3. Expansion in Emerging Markets

CHAPTER 4. GLOBAL WOMEN'S HEALTHCARE MARKET INDUSTRY ANALYSIS

4.1. PORTER'S 5 FORCE MODEL

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
 - 4.2.1. Political
 - 4.2.2. Economical
 - 4.2.3. Social
 - 4.2.4. Technological
 - 4.2.5. Environmental
 - 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL WOMEN'S HEALTHCARE MARKET SIZE & FORECASTS BY DRUGS 2022-2032

5.1. SEGMENT DASHBOARD

- 5.2. Global Women's Healthcare Market: Drugs Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
 - 5.2.1. Prolia

- 5.2.2. Xgeva
- 5.2.3. Evista
- 5.2.4. Mirena
- 5.2.5. Zometa
- 5.2.6. Reclast
- 5.2.7. Nuvaring
- 5.2.8. Premarin
- 5.2.9. Actonel

CHAPTER 6. GLOBAL WOMEN'S HEALTHCARE MARKET SIZE & FORECASTS BY APPLICATION 2022-2032

6.1. SEGMENT DASHBOARD

6.2. Global Women's Healthcare Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

- 6.2.1. Female Infertility
- 6.2.2. Postmenopausal Osteoporosis
- 6.2.3. Endometriosis
- 6.2.4. Contraception
- 6.2.5. PCOS (Polycystic Ovary Syndrome)
- 6.2.6. Menopause

CHAPTER 7. GLOBAL WOMEN'S HEALTHCARE MARKET SIZE & FORECASTS BY REGION 2022-2032

7.1. NORTH AMERICA WOMEN'S HEALTHCARE MARKET

- 7.1.1. U.S. Women's Healthcare Market
 - 7.1.1.1. Drugs Breakdown Size & Forecasts, 2022-2032
 - 7.1.1.2. Application Breakdown Size & Forecasts, 2022-2032
 - 7.1.1.3. Others Breakdown Size & Forecasts, 2022-2032
 - 7.1.1.4. End User Breakdown Size & Forecasts, 2022-2032
 - 7.1.2. Canada Women's Healthcare Market
- 7.2. Europe Women's Healthcare Market
- 7.2.1. UK Women's Healthcare Market
 - 7.2.2. Germany Women's Healthcare Market
 - 7.2.3. France Women's Healthcare Market
 - 7.2.4. Spain Women's Healthcare Market
 - 7.2.5. Italy Women's Healthcare Market
 - 7.2.6. Rest of Europe Women's Healthcare Market
- 7.3. Asia-Pacific Women's Healthcare Market
- 7.3.1. China Women's Healthcare Market

- 7.3.2. India Women's Healthcare Market
- 7.3.3. Japan Women's Healthcare Market
- 7.3.4. Australia Women's Healthcare Market
- 7.3.5. South Korea Women's Healthcare Market
- 7.3.6. Rest of Asia Pacific Women's Healthcare Market
- 7.4. Latin America Women's Healthcare Market
 - 7.4.1. Brazil Women's Healthcare Market
 - 7.4.2. Mexico Women's Healthcare Market
 - 7.4.3. Rest of Latin America Women's Healthcare Market
- 7.5. Middle East & Africa Women's Healthcare Market
 - 7.5.1. Saudi Arabia Women's Healthcare Market
 - 7.5.2. South Africa Women's Healthcare Market
 - 7.5.3. Rest of Middle East & Africa Women's Healthcare Market

CHAPTER 8. COMPETITIVE INTELLIGENCE 8.1. KEY COMPANY SWOT ANALYSIS

- 8.1.1. Bayer AG
- 8.1.2. Amgen Inc.
- 8.1.3. Pfizer Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Bayer AG
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Amgen Inc.
 - 8.3.3. Pfizer Inc.
 - 8.3.4. Merck & Co., Inc.
 - 8.3.5. Teva Pharmaceutical Industries Ltd.
 - 8.3.6. AbbVie Inc.
 - 8.3.7. Eli Lilly and Company
 - 8.3.8. Ferring Pharmaceuticals
 - 8.3.9. Novo Nordisk A/S
 - 8.3.10. Johnson & Johnson
 - 8.3.11. Lupin Limited
 - 8.3.12. Allergan plc
 - 8.3.13. Sun Pharmaceutical Industries Ltd.

8.3.14. Sanofi S.A.

8.3.15. Novartis International AG

CHAPTER 9. RESEARCH PROCESS 9.1. RESEARCH PROCESS

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

List Of Tables

LIST OF TABLES

- TABLE 1. Global Women's Healthcare Market, Report Scope
- TABLE 2. Global Women's Healthcare Market Estimates & Forecasts by Region 2022-2032 (USD Million/Billion)
- TABLE 3. Global Women's Healthcare Market Estimates & Forecasts by Drugs 2022-2032 (USD Million/Billion)
- TABLE 4. Global Women's Healthcare Market Estimates & Forecasts by Application 2022-2032 (USD Million/Billion)
- TABLE 5. Global Women's Healthcare Market Estimates & Forecasts by Procedures 2022-2032 (USD Million/Billion)
- TABLE 6. Global Women's Healthcare Market Estimates & Forecasts by End User 2022-2032 (USD Million/Billion)
- TABLE 7. Global Women's Healthcare Market by Segment, Estimates & Forecasts, 2022-2032 (USD Million/Billion)
- TABLE 8. Global Women's Healthcare Market by Region, Estimates & Forecasts, 2022-2032 (USD Million/Billion)
- TABLE 9. Global Women's Healthcare Market by Segment, Estimates & Forecasts, 2022-2032 (USD Million/Billion)
- TABLE 10. Global Women's Healthcare Market by Region, Estimates & Forecasts, 2022-2032 (USD Million/Billion)
- ...
- TABLE 100. [Additional Tables as per Final Report]

Note: This list is not complete. The final report contains more than 100 tables. The list may be updated in the final deliverable.

I would like to order

Product name: Global Women's Healthcare Market Size study, by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Premarin, Actonel) by Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G8960FFFC5CAEN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8960FFFC5CAEN.html>